10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort A: 6 patients were treated with azer-cel and lymphodepletion (chemotherapy) 1 ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase ...

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and ...